– Durability of Response and Continued Manageable Safety Profile for the Phase 1 and iMMagine-1 Studies with Anito-cel in Patients with Relapsed/Refractory Multiple Myeloma to be Presented by Partner ...
– Initial Results from Kite-753, Optimized with Novel Manufacturing Process That Preserves T-Cell Fitness, Show High Complete Response Rate and Favorable Safety Trend – – Novel Construct for Two ...
KITE-363 showed high response rates and manageable safety in relapsed/refractory B-cell lymphoma patients, with no dose-limiting toxicities reported in phase 1a. Dose level 3 demonstrated the highest ...
– Kite Cell Therapy Business Unit at Gilead Sciences K.K. Will Manage the Sales and Promotion Activities in Japan After the Marketing Authorization Transfer – SANTA MONICA, Calif. & TOKYO--(BUSINESS ...
Gilead Sciences and its Kite cell therapy subsidiary have agreed to acquire Cell Design Labs for up to approximately $567 million, in a deal designed to grow the buyers’ footprint in chimeric antigen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results